Eduardo A. Maura

Mass Tort Litigation / Class Actions - Plaintiffs

0.0 (0 reviews)

Jacksonville, Florida

1+ years experience

Updated: Jan 01, 2026

Contact Information

305-570-2208

https://www.lawayala.com/eduardo-a-maura/

2490 Coral Way, Suite 401 Miami FL US

Create an account to contact this attorney

Claim this profile

Are you this attorney? Claim or manage this listing by signing in or creating an attorney account.

Attorney Login Claim Profile

Bio

Specializing in Mass Tort Litigation / Class Actions - Plaintiffs, Eduardo A. Maura serves the legal needs of Florida residents. Throughout one year in the legal field, Eduardo A. Maura has developed deep expertise in Mass Tort Litigation / Class Actions - Plaintiffs. Eduardo A. Maura combines legal skill with genuine concern for client outcomes. Eduardo A. Maura takes time to listen to client concerns and explain legal processes clearly. Eduardo A. Maura serves Florida with a commitment to professional advocacy and client success.

Local Legal Snapshot

Jurisdiction

Florida

State Capital

Tallahassee

Highest Court

Florida Supreme Court

Bar Association

The Florida Bar

Typical Consultation

$150-$300

Typical Hourly Range

$250-$450/hr

Fee Model Notes

Hourly or flat-fee billing is common.

Estimates vary by market, complexity, urgency, and attorney experience.

Practice Areas

Mass Tort Litigation / Class Actions - Plaintiffs

Awards & Recognition

Recognized: Mass Tort Litigation / Class Actions - Plaintiffs
Practice Area: Commercial Litigation
Practice Area: Commercial Transactions / UCC Law
Practice Area: Construction Law
Practice Area: Litigation - Construction
Practice Area: Litigation - Real Estate
Practice Area: Real Estate Law
$51,971.82 arbitration award. Represented the Claimant against a dealership for the sale of a defective vehicle with a tampered odometer. Obtained Claimant's entitlement to fees as well.
$295,200.00 arbitration award. Represented the Claimant. Dispute by Claimant against manufacturer of medical devices for unpaid commissions on procurement of business with a large U.S. pharmaceutical company.